ARG57064

anti-GALE antibody [6G10]

anti-GALE antibody [6G10] for Western blot and Human

Overview

Product Description Mouse Monoclonal antibody [6G10] recognizes GALE
Tested Reactivity Hu
Tested Application WB
Host Mouse
Clonality Monoclonal
Clone 6G10
Isotype IgG1, kappa
Target Name GALE
Antigen Species Human
Immunogen Recombinant fragment around aa. 1-348 of Human GALE.
Conjugation Un-conjugated
Alternate Names UDP-GlcNAc 4-epimerase; SDR1E1; UDP-galactose 4-epimerase; Galactowaldenase; EC 5.1.3.2; EC 5.1.3.7; UDP-N-acetylglucosamine 4-epimerase; UDP-GalNAc 4-epimerase; UDP-N-acetylgalactosamine 4-epimerase; UDP-glucose 4-epimerase

Application Instructions

Application Suggestion
Tested Application Dilution
WB1:500 - 1:1000
Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist.

Properties

Form Liquid
Purification Purification with Protein A.
Buffer PBS (pH 7.4), 0.02% Sodium azide and 10% Glycerol.
Preservative 0.02% Sodium azide
Stabilizer 10% Glycerol
Concentration 1 mg/ml
Storage Instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use.
Note For laboratory research only, not for drug, diagnostic or other use.

Bioinformation

Database Links

GeneID: 2582 Human GALE

Swiss-port # Q14376 Human UDP-glucose 4-epimerase

Gene Symbol GALE
Gene Full Name UDP-galactose-4-epimerase
Background This gene encodes UDP-galactose-4-epimerase which catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose, and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The bifunctional nature of the enzyme has the important metabolic consequence that mutant cells (or individuals) are dependent not only on exogenous galactose, but also on exogenous N-acetylgalactosamine as a necessary precursor for the synthesis of glycoproteins and glycolipids. Mutations in this gene result in epimerase-deficiency galactosemia, also referred to as galactosemia type 3, a disease characterized by liver damage, early-onset cataracts, deafness and mental retardation, with symptoms ranging from mild ('peripheral' form) to severe ('generalized' form). Multiple alternatively spliced transcripts encoding the same protein have been identified. [provided by RefSeq, Jul 2008]
Function Catalyzes two distinct but analogous reactions: the reversible epimerization of UDP-glucose to UDP-galactose and the reversible epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The reaction with UDP-Gal plays a critical role in the Leloir pathway of galactose catabolism in which galactose is converted to the glycolytic intermediate glucose 6-phosphate. It contributes to the catabolism of dietary galactose and enables the endogenous biosynthesis of both UDP-Gal and UDP-GalNAc when exogenous sources are limited. Both UDP-sugar interconversions are important in the synthesis of glycoproteins and glycolipids. [UniProt]
Calculated MW 38 kDa